Dashboard
1
Flat results in Mar 26
- INTEREST(HY) At CNY 0.9 MM has Grown at 16.79%
- NET SALES(Q) Lowest at CNY 260.35 MM
2
With ROE of 17.08%, it has a fair valuation with a 3.48 Price to Book Value
3
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 7,534 Million (Mid Cap)
18.00
NA
2.38%
-0.60
17.08%
3.66
Revenue and Profits:
Net Sales:
299 Million
(Quarterly Results - Jun 2026)
Net Profit:
81 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
21.8%
0%
21.8%
6 Months
-1.5%
0%
-1.5%
1 Year
-6.21%
0%
-6.21%
2 Years
18.17%
0%
18.17%
3 Years
-13.22%
0%
-13.22%
4 Years
-7.08%
0%
-7.08%
5 Years
-70.97%
0%
-70.97%
Amoy Diagnostics Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.09%
EBIT Growth (5y)
12.03%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.63
Sales to Capital Employed (avg)
0.58
Tax Ratio
12.37%
Dividend Payout Ratio
49.63%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
34.49%
ROE (avg)
15.98%
Valuation key factors
Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
3.07
EV to EBIT
13.62
EV to EBITDA
12.22
EV to Capital Employed
6.18
EV to Sales
4.28
PEG Ratio
0.64
Dividend Yield
2.84%
ROCE (Latest)
45.37%
ROE (Latest)
17.08%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
299.00
307.30
-2.70%
Operating Profit (PBDIT) excl Other Income
115.60
118.00
-2.03%
Interest
1.70
0.70
142.86%
Exceptional Items
1.30
1.40
-7.14%
Consolidate Net Profit
81.00
98.60
-17.85%
Operating Profit Margin (Excl OI)
340.10%
333.20%
0.69%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is -2.70% vs -0.77% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is -17.85% vs 23.71% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,186.20
1,105.40
7.31%
Operating Profit (PBDIT) excl Other Income
420.50
334.30
25.79%
Interest
2.20
1.70
29.41%
Exceptional Items
5.70
-17.20
133.14%
Consolidate Net Profit
361.30
254.90
41.74%
Operating Profit Margin (Excl OI)
305.10%
248.90%
5.62%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 7.31% vs 6.27% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 41.74% vs -2.52% in Dec 2024
About Amoy Diagnostics Co., Ltd. 
Amoy Diagnostics Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






